Cory Renauer News Today

Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner.

The competitive stakes in robotic surgery have never been higher for market pioneer Intuitive Surgical as Medtronic, Johnson & Johnson, and others enter.

The competitive stakes in robotic surgery have never been higher for market pioneer Intuitive Surgical as Medtronic, Johnson & Johnson, and others enter.

These dividend stocks provide sustainable and growing dividends, which are nearly triple the S&P 500's yield.

These three Nasdaq 100 stocks provide market-beating yields and steady growth potential at attractive valuations.

Email By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe at anytime. Please refer to our Financial Services Guide (FSG) for more information. This Service provides only general, and not personalised financial advice, and has not taken your personal circumsta...

Author Bio Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.Follow @coryrenauer Intuitive Surgical (NASDAQ:ISRG) stock has more than quadrupled investors money over the past five years, but it doesnt take much to make them nervous. Despite its resilient competitive advantage, shares of the surgical robotics company have fallen in response to forward-loo...

Author Bio Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.Follow @coryrenauer Earnings season is flying along so quickly that you mightve missed one of the most anticipated fourth-quarter reports in the healthcare space. Abbott Labs (NYSE:ABT) had a lot to say about its performance in 2020 and its plans for the year ahead. In this  Motley Fool Live ...

The coronavirus pandemic continues to pressure one of the company's big operating segments.

Luckily, coronavirus tests aren't this company's only rising source of revenue.